Evidence map›Paper›PMID 35882949›Full record

ArticleScientific reports2022

Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma.

Christopher D Malone, Christopher Egbulefu, Alexander Zheleznyak, Jahnavi Polina, Partha Karmakar, Kvar Black, Monica Shokeen, Samuel Achilefu

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Christopher D MaloneDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA. cmalone@wustl.edu.
Christopher EgbulefuDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Alexander ZheleznyakDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Jahnavi PolinaDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Partha KarmakarDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Kvar BlackDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Monica ShokeenDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Samuel AchilefuDepartment of Radiology, Mallinckrodt Institute of Radiology, Washington University School of Medicine, 4515 McKinley Ave., Floor 2, St. Louis, MO, 63110, USA.
Mallinckrodt (United States) · USWashington University in St. Louis · US

Funding

Washington University Center for Cellular ImagingP30CA091842 · NCI · WASHINGTON UNIVERSITY · PI AIMEE S JAMES · 2001 to 2026
$128.0M
NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPYR01CA260855 · NCI · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL · 2021 to 2025
$3.5M
Exploring CD38 molecular biology and imaging in multiple myeloma pathogenesisR01CA248493 · NCI · WASHINGTON UNIVERSITY · PI SHOKEEN, MONICA · 2020 to 2024
$3.1M
NANOPHOTOSENSITIZERS FOR REGENERATIVE PHOTOTHERAPY OF TUMORSR01EB021048 · NIBIB · WASHINGTON UNIVERSITY · PI ACHILEFU, SAMUEL · 2015 to 2020
$2.3M
NCI NIH HHS P30 CA091842NCI NIH HHS R01 CA248493NCI NIH HHS R01 CA260855NIBIB NIH HHS R01 EB021048
6 · The paper itself

Abstract

While radioembolization with yttrium-90 (Y-90) microspheres is a promising treatment for hepatocellular carcinoma (HCC), lower responses in advanced and high-grade tumors present an urgent need to augment its tumoricidal efficacy. The purpose of this study was to determine whether clinically used Y-90 microspheres activate light-responsive nano-photosensitizers to enhance hepatocellular carcinoma (HCC) cell oxidative stress and cytotoxicity over Y-90 alone in vitro. Singlet oxygen and hydroxyl radical production was enhanced when Y-90 microspheres were in the presence of several nano-photosensitizers compared to either alone in cell-free conditions. Both the SNU-387 and HepG2 human HCC cells demonstrated significantly lower viability when treated with low activity Y-90 microspheres (0.1-0.2 MBq/0.2 mL) and a nano-photosensitizer consisting of both titanium dioxide (TiO

Indexed as

Carcinoma, HepatocellularEmbolization, TherapeuticLiver NeoplasmsCell DeathHumansMicrospheresOxidative StressPhotosensitizing AgentsYttrium RadioisotopesPhotosensitizing AgentsYttrium-90Yttrium Radioisotopes

Identifiers

PMID35882949
PMCPMC9325688
OpenAlexW4288077820

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.